Where Wegovy has genuine advantages over Mounjaro

The misconception worth setting aside: Wegovy is just 'the weaker one'

There's a shorthand doing the rounds that Mounjaro is simply superior and Wegovy is yesterday's news. It's understandable, the SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, did find that tirzepatide produced greater average weight reduction than semaglutide 2.4mg over 72 weeks. That result is real and worth knowing. But it tells only part of the story, and for many people Wegovy's profile is the clinically stronger fit.

Semaglutide's track record spans more than a decade in diabetes treatment before it became Wegovy. That depth of real-world data is genuinely valuable; it means clinicians have a richer picture of long-term tolerability and safety signals. Mounjaro, as a dual GIP/GLP-1 agonist, is newer. More effective on average in trials, yes, but 'more effective on average' and 'right for this patient' are different questions, and they're exactly what a prescriber works through with you. If you want to dig into whether Wegovy or Mounjaro is the better choice for your situation, that page works through the question carefully without landing on a one-size-fits-all verdict. If you're considering making a change between the two, our guide to moving from Mounjaro to Wegovy explains what that transition typically involves in practice. If you're comparing the two medicines more broadly, the detailed Wegovy vs Mounjaro comparison on this site lays out both sides without a verdict.

Wegovy's specific advantages in 2026

Three areas stand out. First, cardiovascular evidence: semaglutide holds a UK licence for reducing the risk of major cardiovascular events in eligible adults with established heart disease and obesity, a separate, hard indication backed by its own large outcome trial. Tirzepatide does not yet have an equivalent UK cardiovascular indication. For someone with heart disease alongside obesity, that distinction matters to a prescriber.

Second, the oral option. On 11 June 2026 the MHRA approved the Wegovy tablet, the first oral GLP-1 medicine licensed in the UK for weight management. A once-daily tablet, taken before breakfast on an empty stomach, removes the injection step entirely. OASIS 4 phase-3 trial data reported around 13.6% average weight loss at 64 weeks, rising to roughly 17% among participants who adhered fully to treatment. There is no oral tirzepatide equivalent currently available in the UK. For patients who prefer tablets over injections, this is a straightforward advantage. You can read more about treatment options at nume including how the oral route fits in.

Third, the higher injectable dose. The MHRA approved a dedicated 7.2mg weekly Wegovy pen on 14 April 2026, per the GOV.UK announcement. At 7.2mg, trial data showed around 20.7% average weight loss over 72 weeks, closing the gap with Mounjaro's highest-dose results considerably. The clinical picture is less clear-cut than the shorthand suggests.

How the two medicines compare at a glance

That contraception point is one our prescribers discuss at consultation) it affects practical planning for many patients. NHS England's guidance on weight-management injections covers this in detail.

Which medicine suits you, and how to find out

A comparison table can tell you what differs; it cannot tell you which difference matters most for your health. Someone with cardiovascular disease may find semaglutide's indication directly relevant. Someone who travels constantly and wants to avoid refrigerating an injection pen may find the Wegovy tablet changes the decision entirely. Someone who has already tried semaglutide without the results they hoped for might be a good candidate for tirzepatide's dual mechanism. These aren't arbitrary preferences, they're clinical factors.

If you've already been on one of these medicines and are thinking about switching, the guide on moving from Mounjaro to Wegovy covers what that process typically involves. Questions about cost often come up here too, why Wegovy tends to be priced lower than Mounjaro is a practical question with a straightforward answer. For a side-by-side breakdown of how the two medicines stack up on efficacy, side effects and suitability, the Wegovy v Mounjaro page covers the key differences in one place. Our clinical team reviews every consultation personally; no automated approval, no algorithm scoring. Which of these medicines, if either, is right for you is a clinical decision made with a prescriber, not a comparison article. Speak to our prescribers through a free consultation and get an answer grounded in your own health picture.